84 Total results for product and free and sample content found
With over 63 million confirmed cases and over 1.4 million deaths worldwide as of the start of December, the COVID-19 pandemic has certainly lit a fire under the pharmaceutical industry in the pursuit of therapeutics. In the process, with the recent emergency use authorisation in the UK for Pfizer and BioNTech’s BNT-162b2 vaccine, and the 94.5% efficacy reported by Moderna for its mRNA-1273 vaccine, a new technology has shot to the forefront: the mRNA vaccine.
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit.
Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biom...
Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor...
With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target
Last year, a total of 67 biopharma and medtech companies completed initial public offerings (IPOs), raising for $8.55bn combined.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, Citeline
“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
AI applications are as varied as the industry sectors that use them, and pharma has discovered the specific types of AI most useful in achieving faster, more positive results across a wide range of industry activities.
Pharmaceutical industry experts agree that the future of pharma depends on the use of Big Data to predict upcoming events and markets, gain insights into new opportunities, and understand the implications of competitors’ activities.
No Records Found